AbbVie’s Rinvoq Growth Slows to 20.2% While Skyrizi Gains 29.2%
MRK•AbbVie’s Rinvoq quarterly sales rose 20.2% year-over-year, down from 28.6% in the prior quarter, highlighting a deceleration in its key immunology asset. With Rinvoq on track for $10.2 billion in 2026 sales—over 15% of AbbVie’s expected $67.3 billion revenue—the company will lean heavily on Skyrizi’s 29.2% growth.
1. Rinvoq Growth Deceleration
Rinvoq’s global sales rose 20.2% in the latest quarter, down from 28.6% in the prior period, marking the first noticeable slowdown in the drug’s expansion. This deceleration raises questions about market penetration limits and the sustainability of its growth trajectory over the coming quarters.
2. Skyrizi Continues Strong Momentum
Skyrizi posted 29.2% year-over-year sales growth, outpacing Rinvoq and serving as a critical pillar of AbbVie’s immunology lineup. Strong demand for Skyrizi partly offsets concerns around Rinvoq, but places heavier performance expectations on this asset.
3. Revenue and Valuation Implications
Rinvoq is projected to generate $10.2 billion in sales this year, representing over 15% of AbbVie’s expected $67.3 billion revenue. Investors will closely watch whether the slowed growth justifies current stock valuations and long-term earnings forecasts.
4. Competitive Landscape Risk
The slowdown in Rinvoq could signal initial impact from emerging immunology competitors targeting similar indications. Any continued deceleration may force AbbVie to accelerate new product launches or adjust pricing strategies to maintain its market share.
